Powering the future through multiscale modelling of nuclear reactor materials
The Innovation Platform · 2026
DOI: 10.66233/innp-027-30256 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Innovation Platform, 2026. Verfasst von Michael R Tonks.
Abstract (Originalsprache)
Powering the future through multiscale modelling of nuclear reactor materials As demand for nuclear energy surges, computational materials design offers a faster, safer path towards developing new reactors. The world is experiencing a dramatic resurgence of interest in nuclear energy. Driven by surging electricity demand from data centres, artificial intelligence (AI) infrastructure, and the broader digitalisation of society, governments and energy companies across North America, Europe, and Asia are committing to new reactor construction at a pace not seen in decades. Small modular reactors, high-temperature gas-cooled reactors, molten salt reactors, and fast reactors are moving from concept to deployment with remarkable speed, each promising cleaner, more reliable power for a world in urgent need of low-carbon energy. But the path from reactor concept to operating plant runs directly through one of the hardest problems in materials science: developing materials that can survive, and perform reliably, in some of the most extreme environments on Earth. Without advances in how those materials are discovered, tested, and qualified for use, the promise of next-generation nuclear power risks being delayed by decades.
Zitieren
APA
Tonks, M. R. (2026). Powering the future through multiscale modelling of nuclear reactor materials. The Innovation Platform. https://doi.org/10.66233/innp-027-30256
Vancouver
Tonks MR. Powering the future through multiscale modelling of nuclear reactor materials. The Innovation Platform. 2026. doi:10.66233/innp-027-30256
BibTeX
@article{Tonks2026,
author = {Tonks, Michael R},
title = {Powering the future through multiscale modelling of nuclear reactor materials},
journal = {The Innovation Platform},
year = {2026},
doi = {10.66233/innp-027-30256}
}
EUVIMED